Completed
Kinetics in Time-lapse Culture of Human Preembryos
What is being collected
Data Collection
Collected from today forward - ProspectiveWho is being recruted
Urogenital Diseases+4
+ Genital Diseases
+ Female Urogenital Diseases and Pregnancy Complications
From 38 to 45 Years
+12 Eligibility Criteria
How is the trial designed
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Observational
Study Start: January 2013
Summary
Principal SponsorFerring Pharmaceuticals
Last updated: August 28, 2017
Sourced from a government-validated database.Claim as a partner
Study start date: January 1, 2013
Actual date on which the first participant was enrolled.This post-marketing, single-center prospective study will be conducted in an open-label, non-interventional setting, for women seeking fertility treatment and will describe cleavage dynamics in relation to the age of the oocyte and gonadotrophin treatment.
Principal SponsorFerring Pharmaceuticals
Last updated: August 28, 2017
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
356 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Female
Biological sex of participants that are eligible to enroll.From 38 to 45 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Urogenital DiseasesGenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleInfertilityFemale Urogenital DiseasesInfertility, Female
Criteria
7 inclusion criteria required to participate
Follicle stimulation with Bravelle and/or Menopur
IVF/ICSI treatment
Long agonist or short antagonist treatment
Regular cycles of 25-35 days
Show More Criteria
5 exclusion criteria prevent from participating
BMI more than 35
FSH more than 13 or antral follicle count (AFC) less than 4 at fertility investigation
Known allergic reactions to the planned medications
Presence of hydrosalpinx on ultrasound
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
2 intervention groups are designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
CompletedOne Study Center